Skip to main content
Pure Biologics S.A. logo

Pure Biologics S.A. — Investor Relations & Filings

Ticker · PUR ISIN · PLPRBLG00010 LEI · 2594002TXS19AUYHIF82 WAR Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2023-04-21 Capital/Financing Update
Country PL Poland
Listing WAR PUR

About Pure Biologics S.A.

https://purebiologics.com/

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Recent filings

Filing Released Lang Actions
Zawarcie Umowy Inwestycyjnej oraz Umowy Pożyczki przez Spółkę - Content (PL)
Capital/Financing Update Classification · 99% confidence The document text details the execution of an investment agreement and a loan agreement between the Issuer (Spółka) and an Investor (ACRX Investments Limited). Key elements include the loan amount (12,000,000.00 PLN), conversion options into new shares (Akcje Konwertowane), issuance of warrants (Warranty), and conditions precedent involving shareholder resolutions (Uchwała) regarding capital increase and board appointments. These actions—securing financing, issuing debt convertible into equity, and setting terms for future capital structure changes—are characteristic of a significant financing or capital structure event. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend notice (DIV). Since it details the terms of a new financing arrangement, CAP is the most appropriate classification.
2023-04-21 Polish
Nominowanie kandydata wiodącego w projekcie PB004 - Content (PL)
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from the Management Board (Zarząd) of Pure Biologics S.A. It details a significant milestone in their drug development pipeline (Project PB004), specifically the selection of a lead candidate (PBA-0405) for further preclinical and clinical development. It outlines future plans, timelines (Q2 2023, Q2 2024, end of 2024), and financing secured for this development. This content strongly aligns with updates regarding corporate strategy, financing, and material operational progress, which often falls under general regulatory disclosures or specific financing/capital updates. Since it discusses securing funding (48 mln zł) and advancing a key project towards commercialization, it fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if it were a general disclosure. Given the focus on securing funds and advancing the project timeline, CAP is a strong candidate, but because it is a specific, material update on strategic progress and financing related to R&D, it is often classified as a general regulatory announcement if a more specific category like 'R&D Update' is unavailable. However, the text explicitly mentions securing funding ('zabezpieczyła łącznie ok. 48 mln zł na współfinansowanie') and achieving a strategic milestone, making 'Capital/Financing Update' (CAP) highly relevant. Since it is a detailed update on strategic progress and financing rather than just a simple announcement of a dividend or share issue, and it's not a standard financial report (10-K, IR), CAP or RNS are the closest fits. Given the explicit mention of securing financing for development, CAP is chosen over the general RNS fallback.
2023-04-13 Polish
Nominowanie kandydata wiodącego w projekcie PB003G - Content (PL)
Regulatory Filings Classification · 100% confidence The document is a formal announcement from the Management Board (Zarząd) of Pure Biologics S.A. It details the selection of a lead candidate (PBA-0091) for further preclinical and clinical development under project PB003G, outlines the scientific rationale, and provides a timeline for upcoming milestones (Phase 0 and Phase 1 clinical trials) and funding secured. This content relates directly to the company's ongoing research, development pipeline, and strategic progress, which falls under general corporate updates or investor information, but is not a standard regulatory filing like 10-K, ER, or IR. Since it discusses strategic development and milestones, it is best classified as an Investor Presentation (IP) if it were a presentation, or more generally, a significant corporate update. Given the options, it describes strategic progress and development plans, which often accompany Investor Presentations or are released as significant corporate news. However, it is a detailed narrative update on R&D progress and future plans, which aligns closely with the scope of an Investor Presentation (IP) or a detailed Management Report (MDA). Since it is a narrative update on strategic progress and pipeline advancement rather than a formal financial results explanation (MDA) or a slide deck (IP), and it is a significant corporate event, it fits best under a general corporate update category. Given the specific definitions, it is a significant update on the company's core product development pipeline and strategy. It is not a standard financial report, earnings release, or transaction notice. It is a detailed update on R&D progress and future strategy, making 'Investor Presentation' (IP) or 'Management Reports' (MDA) plausible. Since it reads like a detailed press release outlining strategic progress and pipeline advancement, and is not explicitly a financial results discussion (MDA), 'Investor Presentation' (IP) is a strong fit for strategic pipeline updates, although it is presented as a formal announcement. Given the context of pipeline advancement and strategic goals, IP is the most appropriate fit among the choices for a detailed strategic update.
2023-04-05 Polish
Sprawozdanie Biegłego Rewienta z badania JSF MSSF 2022 Pure Biologics S.A. - podpis
Regulatory Filings Classification · 95% confidence The provided document text consists entirely of XML digital signature blocks (Signature, SignedInfo, KeyInfo, Object, etc.) and certificate data. This structure is characteristic of a digitally signed document, often used to ensure the authenticity and integrity of a filing. The document length is short (4469 characters). Since the content is purely metadata about the signature and does not contain the actual financial report content (like an Annual Report, Earnings Release, or Interim Report), it is most likely an announcement that a document has been signed and published, or it is the signature block accompanying a filing that is not the primary content. Given the options, and the nature of this being a technical attachment/metadata rather than a standard report, the most appropriate classification is the general fallback for regulatory filings that don't fit specific content types, or an announcement of publication. Since there is no explicit text stating 'Report attached' or 'Publication announced', but the content is clearly technical metadata accompanying a filing (indicated by the reference to 'PUREBIOLOGICSSzBJSFMSSF2022.xhtml'), classifying it as a general Regulatory Filing (RNS) is the safest choice, as it is not the report itself (10-K, IR) nor a specific announcement type like DIV or ER.
2023-03-31 Polish
Sprawozdanie Biegłego Rewienta z badania JSF MSSF 2022 Pure Biologics S.A.
Audit Report / Information Classification · 100% confidence The document text is titled "Raport SPRAWOZDANIE NIEZALEŻNEGO BIEGŁEGO REWIDENTA Z BADANIA ROCZNEGO SPRAWOZDANIA FINANSOWEGO PURE BIOLOGICS S.A. ZA ROK OBROTOWY ZAKOŃCZONY 31 GRUDNIA 2022 R." which translates to "Report of the Independent Auditor on the Audit of the Annual Financial Statements of PURE BIOLOGICS S.A. for the financial year ended December 31, 2022." The content explicitly discusses the audit process, the opinion given on the financial statements (including balance sheet, income statement, cash flow statement), key audit matters, and the responsibilities of the management and the auditor, all standard components of an Audit Report. This directly matches the definition for 'Audit Report / Information' (AR). Although it relates to the annual financial statements, the document itself is the auditor's opinion/report, not the full Annual Report (10-K) or an announcement of the report (RPA). FY 2022
2023-03-31 Polish
Jednostkowe Sprawozdanie Finansowe Pure Biologics S.A. za okres 01.01.2022-31.12.2022 - podpisy
Regulatory Filings Classification · 95% confidence The document text consists entirely of XML-based digital signature metadata (XAdES/XML-DSIG) for a financial report file named 'Pure_Biologics_SA_Jednostkowe_Sprawozdanie_Finansowe_za_okres_01_01_31_12_2022.xhtml'. This is a technical wrapper used to certify the authenticity of a financial statement. Per the 'Certification Rule', documents that are primarily certifications or attestations of a report, rather than the report itself, should be classified as Regulatory Filings (RNS). FY 2022
2023-03-31 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.